

Oishi Symposium

Thursday, April 4, 2024 8 am – 11:30 am Seattle, Washington





Welcome and Announcements

Connie Szczepanek, RN, BSN, CCRP Chair, SWOG Oncology Research Professionals Committee

Deb Bergevin, BS Co-Chair, ORP Education Subcommittee

Joyce Nancarrow Tull, MSN, RN Co-Chair, ORP Education Subcommittee









In honor of and with gratefulness for

Noboru Oishi MD (1928 – 2020)

and

Jeri Oishi, RN



Logistics Details



- Please keep your phone on mute to help with sound quality.
- Questions can be submitted all throughout the meeting via the CHAT icon. We will present them to the speakers during the meeting.
- The presentations will be posted on the SWOG website within a few weeks.







Although there are no formal CE credits for this meeting, you may print a copy of the agenda to reflect your attendance (e.g.: for use with SOCRA or

ACRP).

The second second second as have a feature of the second s

ORP Jeri & Noboru Oishi Symposium

Thursday, April 4, 2024 8:00 AM - 11:30 AM PT

Open, Welcome, and Announcements Connie Szczepanek, Joyce Tull

Blospecimens: Quality, Compliance, and Tips 'n Tricks Phyllis Goodman, Cathy Rankin, Kae Tegtmeier, Erin Cebula, Desiree Goldstein

Break

DEI Champions: Lessons Learned & Implications for Future Programming Colmar Figueroa-Moseley

Break

SWOG QA Audits: Top Ten Deficiencies Laura Gonzales

Break

Tour of SWOG Website Christine Magner

> PLEASE KEEP THIS AGENDA AND USE THE FILLABLE STATEMENT BELOW TO DOCUMENT YOUR EDUCATIONAL CREDITS

I certify that I attended _____ hours of this meeting. The topics of the meeting contribute to the education and professional advancement in clinical research.

Signature Date

Olshi Education Sub-committee Co-Chairs: Deb Bergevin, BS – deb.bergevin@seattlechildrens.org Joyce Nancarrow Tull, MSN, RN – jntull@ucdavis.edu





YOU are The ORP Committee!



"SWOG holds a fundamental conviction that the <u>O</u>ncology <u>R</u>esearch <u>P</u>rofessionals (ORP) play a crucial role in the successful development, implementation, and analysis of any SWOG clinical trial."





ORP Executive Committee Members

Deb Bergevin	Erin Cebula	Joyce Nancarrow-Tull
Lisa Stoppenhagen	Sandy Annis	Dana Little
Connie Szczepanek	Liz Edwards	Anthony Hicks
Annette Betley	Caitlin Hutchinson	Jamie Myers









Chair: Connie Szczepanek Vice-Chair: Dana Little



SWOG Cancer Research Network's Mission

• To significantly improve lives through cancer clinical trials and translational research.

ORP Committee Mission

 To support SWOG activities through promotion of integrity and excellence in clinical research through education, guidance, & collaborative contributions.







Quick Reference

See the ORP page on the SWOG Website:

Member Resources > Oncology Research Professionals

Quick Access to:

- Contact info of Committee Leaders
- Lead ORP (Head CRA) Training Modules
- APP Workshop

23	SWOG	SER ARCH NORK		٩	Directory	8
About	The SWOG Network	News & Events	Clinical Trials	Member Resource	s For Patients	
м	ember Resources	۲				

Oncology Research Professionals

The Oncology Research Professionals (ORP) committee is the largest in the SWOG Cancer Research Network. Members are a diverse mix of nurses, clinical research professionals, pharmacists, quality managers, and other front-line site staff. They play critical accrual and accountability roles at SWOG, as they consent patients to trials, ensure protocols are followed, and oversee data and safety monitoring functions at hospitals, cancer centers, and clinics. Convittee members prenote integrity and excellence in clinical research through education, training, networking and colaborative centributions. At each group meeting, they organize the key for Nobor Oldh Symposium -SWOS synpture event for encology research professionals, as well as the site operations, nursing research committee, and ORP open forum sessions. They als serve as illians on each protocol-producing committee and provide their front-line perspective to trials as they are conceved and managed.

To get more involved please complete the ORP Membership Application

Executive Committee Leadership

Chair: Connie Szczepanek, RN, BSN, CCRP connie szczepanek@crcwm.org

Vice Chair: Dana Little, BA, CCRP dalittle@ucdavis.edu

Nursing Research Lead: Jamie Myers, PhD, FN, AOCNS Jmyers@kumc.edu

ORP Liaisons Leads: Sandy Annis, BA, CCRP <u>aannis2@kumc.edu</u> Erin Cebula, MPH, CCRP <u>erin, cebula@urmc.rochester.edu</u>

Membership Leads: Anthony Hicks, BS, CCRP <u>anthony.bicks@crcwm.org</u> Lisa Stoppenhagen, BS, CCRP, RHIT <u>stoppen@siles.org</u>

Education Leads: Deb Bergevin, BS <u>dbergevin/Bseattiecca.org</u> Joyce Nancarrow-Tuli, MSN, RN, CCRP <u>intull@ucdavis.edu</u>

Site Operations Leads: Connie Sozepanek, RN, SSN, CCRP connie szczepanek@crcwm.org Cartin Hutchinson, MS Caltin hutchinson/ziewa.goz Elizabeth K, Edwards, BS, CCPP <u>edwardel Biohusedu</u>

New Resources

Check out the resources shared at the SWOG Spring 2023 Group Meeting and the SWOG Fall 2023 Group Meeting







A program of the National Cancer Institute of the National Institutes of Health



Get Involved with ORP

Follow the link to the ORP Membership Application on the ORP Member Resources page:

To get more involved please complete the ORP Membership Application.

Key Involvement Opportunities

- Disease Specific Liaisons
- Liaisons at Large
- Education Team







Lung-MAP Site Coordinator's Committee (SCC) Applications Open This Spring!

What We Do:

- Represent NCTN sites currently working on Lung-MAP
 - Academic, NCORP & VA sites
 - Clinical & Regulatory Professionals
- Collaborate on a committee of 8-12 voting members
- Review & recommend strategies/materials to enhance
 accrual

- Provide Lung-MAP newsletter content
- Review & provide feedback on Lung-MAP protocols/materials
- Promote & represent Lung-MAP at the SWOG Group Meetings
- Serve as Lung-MAP mentors & champions at study sites

Interested in Joining?

Email SCC Chair, Stephanie Reyes (<u>smiths1@sjchs.org</u>) for an opportunity to shadow the April 4th Lung-MAP Site Coordinators Committee (SCC) Meeting (Invitation & In-Person Only)

Be on the lookout for the SWOG announcement & memo posted in CTSU!







SWOG Biospecimens: Quality, Compliance and Tips 'n Tricks Phyllis Goodman, M.S. and Kae Tegtmeier





Swog Trials

Phyllis Goodman, M.S. Coordinating Statistician Institution Performance SWOG Statistics and Data Management Center pgoodman@fredhutch.org





Uses for Biospecimens

- Pathology review for eligibility → rarely. Currently only on S1806.
- Platform trials (Lung-MAP, MyeloMATCH, ComboMATCH, iMATCH)
 - Determine appropriate trials for participants based on bio-markers
 - Screening steps
- Determination of next step (S1929, screening)
- Determination of stratification (S1201 ERCC1, HER2 analysis; S1418 PD-L1 evaluation)
- Endpoint determination (MRD in leukemia, myeloma)
- Translational medicine (TM) analyses
- Future research





Value of our Biospecimens


- Biologic data from our specimens
 - Blood, blood products
 - Tissue, bone marrow aspirate
 - Stool, Urine
 - Toenails???
- Linked to clinical data from our trials
 - Demographics
 - Baseline characteristics, disease characteristics
 - Quality of Life
 - Outcomes





S1403 – Circulating Tumor DNA (ctDNA)

- Randomized Phase II trial in patients with EGFR Mutation Positive NSCLC
- Streck Cell-Free collection tubes at baseline, Cycle 3 Day 1 (C3D1) and progression
- Complete clearance of EGFR mutation in ctDNA by C3D1 was associated with a significant decreased risk of progression and death compared to those with persistent ctDNA at C3D1







S1216 – Serum Bone Markers

- Randomized Phase III trial
- Newly diagnosed metastatic prostate cancer; majority have bone disease
- Can measuring 4 bone markers from serum (BAP, CICP, CTx, PYD) help identify survival prognosis?
- Formed 3 risk groups based on combinations of the bone markers with optimal cutpoints → Strongly correlated with survival

Survival from Randomization for 3 Risk Groups Based on Bone Markers







Groupings based on mRNA from bladder cancer tissue The Cancer Genome Atlas (TCGA)




data

based on preliminary



S1314 – Bladder Tissue

- S1314 phase II trial in patients with muscle invasive bladder cancer
- TURBT = transurethral resection of bladder tumor done at study entry
- Convenient disease setting to study cancer tissue
- Performed mRNA analysis to validate prior work from TCGA and assign subtype to each patient
- Correlated subtypes with survival in \$1314







So many specimens!

	NCTN (n=51 protocols)	NCORP (n=8 protocols)
# Blood samples		
Baseline, average (range)	2.1 (0-5)	2.9 (2 - 5)
Post baseline, average (range)	6.3 (0-16)	6.2 (2 - 11)
Tissue/Bone Marrow Aspirates	3.1 (0 - 11)	0.125 (0 – 1)
SWOG studies - Total expectations	posted	
Bloods	87,176	36,412
Tissue	49,680	1,029
Other	3,250	9,712





Available resources

• Protocols

PRIVILEGED COMMUNICATION FOR INVESTIGATIONAL USE ONLY

SWOG CANCER RESEARCH NETWORK

S2212, SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY

This trial is part of the National Clinical Trials Network (NCTN) program, which is sponsored by the National Cancer Institute (NCI). The trial will be led by SWOG with the participation of the network of NCTN organizations: Alliance for Clinical Trials in Oncology; ECOG-ACRIN Cancer Research Group; and NRG.

> NCT# TBD Study Exempt from IND Requirements per 21 CFR 312.2(b)



SWOG CANCER RESEARCH NETWORK CRA About The SWOG Network News & Events Clinical Trials Member Resources Workbench Home / Member Resources / CRA Workbench **CRA Workbench** Popular Resources CRA **OPEN Patient Registration**

Rave Data Submission

Specimen Tracking

SWOG OA / Audits /

Monitoring

Workbench Your resource headquarters for SWOG clinical trial patient management

Directory PHYLLIS

Latest CRA

Newsletter

Specimen Tracking Swog Research

Chooser	Welcome to the SWOG Specimen Tracking Website
Log a Specimen	You are logged in as a user for WA020 - University of Washington Medical Center - Montlake
Specimen Manager	Important Announcements:
View/Update Consent Answers	3/29/2024
<u>Notify that Specimen Cannot b</u> Submitted	specimen Labelling
Reports	 Basic Labels: Use for fresh or frozen blood or bone marrow products (e.g., whole blood, plasma, serum, buffy coat, bone marrow and fresh or frozen urine). Iissuc Labels: Use for tissue specimens (FFPE or snap-frozen), including stained and unstained slides as well as blocks, scrolls, or other sections.
	 Tissue with Microns Labels: Use for tissue specimens that require thickness information.





SUBMISSION OVERVIEW TABLE

Protocol – Section 15

- Summary table with specimen requirements
 - Specimen types, timepoints
 - Mandatory vs. required with consent
 - Labelling requirement
 - Lab to ship to
- Working to get this table into every protocol with specimens
- Details in subsequent sub-sections
- Section 12 will have the how and why of pathology review (if there is) but the specimen details will be in Section 15

|--|--|

	Specimen	Collection	Timepoint	Required	Ship To
	Peripheral	EDTA (Lavender	 Pre-treatment 	Required if	SWOG
	Blood	Top)	(Cycle 1, Day 1)	participant	Biospecimen
			 40 weeks after 	consents	Bank
			randomization		
			 3 years after 		
			registration		
	Peripheral	 Roche <u>cf</u>-DNA Blood 	 Pre-treatment 	Required if	SWOG
	Blood	Collection Tubes	(Cycle 1, Day 1)	participant	Biospecimen
			 40 weeks after 	consents	Bank
			randomization		
			 3 years after 		
┡│			registration		
נן			 5 years after 		
			registration		
	Biopsy Tissue	 FFPE block 	 Baseline (submitted 	Required if	SWOG
		(preferred)	to SWOG within 30	participant	Biospecimen
			days after	consents	Bank
		OR	randomization)		
			 At the time of 		
		 1 high-quality, 4–5- 	recurrence/progress		
		micron H&E slide **	ion, if biopsy is		
		and 15 unstained, 4-	performed per		
		5 micron, positively-	treating investigator		
		charged slides **	preference.		



swog.org

SWOG CANCER RESEARCH NETWORK

Biospecimen Collection and Submission Procedures

This webpage provides links to specimen labeling, co packaging, and shipment instructions and handouts SWOG Cancer Research Network Biospecimen Bank indicated in the protocol, these instructions may also laboratories.

- For specimen instructions: First, refer to the protocol
 - Always follow protocol-specific instructions pr linked resource. Those instructions su
 - For SWOG-led protocols: Specimen ins linked resource.

Publications

Institutions

General Specimen Requirements and Instructions:

When the protocol does not provide specimen instructions (or refers to the SWOG website for instructions), follow the instructions below for the relevant specimen type(s). Each of the following webpages includes downloadable 1-page handouts for ease of site (and designated staff) use.

Clinical Trials

Specimen Labeling

The complete guidelines are also posted here for download.

The complete guidelines are also posted here for download.





Directory


Member Resources

PHYLLIS

For Patients

A program of the National Cancer Institut

Specimen Information – CRA Workbench



SWOG



Join the CRA Mailing list

Directory PHYLLIS

Act on behalf

Specimen Tracking

SWOG Best Practices



Best Practices: Specimen Submission - Guidance

SWOG CANCER RESEARCH NETWORK

Best Practices for SWOG Studies

NOTES: Specimen Submission

Unless indicated otherwise in Section 15 of the protocol, specimens should be submitted per the following guidelines:

- All specimens must be logged into the SWOG online Specimen Tracking system.
- Baseline tissue specimens must be shipped within 30 days after registration or within 30 days after surgery performed after registration unless otherwise stated in the protocol.
- Ambient temperature blood specimens must be shipped within one day of collection.
- Frozen blood and urine specimens must be shipped within 15 days of collection.
- If batch shipping of frozen specimens is allowed per protocol, they must be shipped at intervals no longer than every 3 months unless otherwise specified in the protocol. Batch shipments should include specimens for no more than 5 patients and no more than 50 individual specimens.
- Shipment of specimens greater than 3 months after the due date will result in a major data quality deficiency during an audit.





Specimen Tracking System

<u>Chooser</u>	Welcome to the SWOG Specimen Tracking Website
<u>Log a Specimen</u>	You are logged in as a user for WA020 - University of Washington Medical Center - Montlake
<u>Specimen Manager</u>	Important Announcements:
<u>View/Update Consent Answers</u> Notify that Specimen Cannot be	<u>3/29/2024</u> Specimen Labelling
<u>Submitted</u> Reports Administration	 Basic Labels: Use for fresh or frozen blood or bone marrow products (e.g., whole blood, plasma, serum, buffy coat, bone marrow and fresh or frozen urine). Tissue Labels: Use for tissue specimens (FFPE or snap-frozen), including stained and unstained slides as well as blocks, scrolls, or other sections. Tissue with Microns Labels: Use for tissue specimens that require thickness information. Time-based Labels: Use for fresh or frozen blood products where multiple samples are collected during the
<u>Contact Us</u>	course of a day and the lab requires collection time to differentiate the samples for processing.
Version 3.0	Training module with demo for using the Specimen Tracking System.
	Written Instructions for using the Specimen Tracking System (English).





Specimen Tracking Training

😑 🕒 YouTube

Search

Picture in picture

Specimen Tr

Using the SWOG Specimen Tracking System

Contents

Logging On	1
Home Page	2
Log a Specimen	
Specimen Manager	
Notify that Specimen Cannot be Submitted	7
Reports	7
Administration	8
Contact Us	9
Questions or problems?	9

Prese Christin Clinical Researc SWOG Data C

0:10 / 21:43





Specimen Tracking – Log a Specimen

		Registration Step	Submission Timepoint		specimen has been logged already specimen was reported as unsubmittable	Material Requirements	Lab
SWOG Patien Patient Init	_	1	Baseline, Pre-Treatment	S <u>Tissue from primary site</u>	Blocks FFPE	Preferred	201 - SWOG Specimen Repository Columbus, OH
		1	Baseline, Pre-Treatment	Tissue from primary site	Stained Slides H&E Slides	Alternate	201 - SWOG Specimen Repository Columbus, OH
Step 2 of 3	3: Choose the spe	1	Baseline, Pre-Treatment	Tissue from primary site	Unstained Slides	Alternate	201 - SWOG Specimen Repository Columbus, OH
	SELECT ONE OR MORE	1	Baseline, Pre-Treatment	Example 2 Metastatic tissue from distant site	Blocks FFPE	Preferred	201 - SWOG Specimen Repository Columbus, OH
	CLICK APPLY TO DISPL	1	Baseline, Pre-Treatment	8 Metastatic tissue from distant site	Stained Slides H&E Slide from Metastatic Tissue	Alternate	201 - SWOG Specimen Repository Columbus, OH
	Lab = All	1	Baseline, Pre-Treatment	8 Metastatic tissue from distant site	Unstained Slides Unstained Slides from Metastatic Tissue	Alternate	201 - SWOG Specimen Repository Columbus, OH
	Specimen/Material Typ	1	Relapse/progression, At Disease Progression	Tissue from primary site	Blocks	Preferred	201 - SWOG Specimen Repository Columbus, OH
		1	Relapse/progression, At Disease Progression	Tissue from primary site	Unstained Slides	Alternate	201 - SWOG Specimen Repository Columbus, OH
	Submission Timepoint	1	Relapse/progression, At Disease Progression	Metastatic tissue from distant site	Blocks	Preferred	201 - SWOG Specimen Repository Columbus, OH
		1	Relapse/progression, At Disease Progression	Metastatic tissue from distant site	Unstained Slides	Alternate	201 - SWOG Specimen Repository Columbus, OH
		1	Relapse/progression, At Disease Progression	Metastatic tissue from local site	Blocks	Preferred	201 - SWOG Specimen Repository Columbus, OH
Study Number	r: S1802	1	Relapse/progression, At Disease Progression	Metastatic tissue from local site	Unstained Slides	Alternate	201 - SWOG Specimen Repository Columbus, OH
		1	Baseline, Pre-Registration	Solution States	Whole Blood 5 mL, Purple Top EDTA Tube, Room Temp.	Only option	201 - SWOG Specimen Repository Columbus, OH
		1	Baseline, Step 1 Registration	Blood	Whole Blood 7.5 mL, RareCyte tube, Room Temp.	Only option	181 - Amir Goldkorn Lab Los Angeles, CA
Registration	Step Submission Time	1	Baseline, Step 1 Registration	Blood	Whole Blood 7.5 mL, Streck DNA tube, Room Temp.	Only option	181 - Amir Goldkorn Lab Los Angeles, CA
		1	Baseline, Step 1 Registration	Blood	Whole Blood 7.5 mL, PAXgene RNA tube, Room Temp.	Only option	181 - Amir Goldkorn Lab Los Angeles, CA
Please sele	ect a required filte	1	Relapse/progression, Disease Progression	Blood	Whole Blood 7.5 mL, RareCyte tube, Room Temp.	Only option	181 - Amir Goldkorn Lab Los Angeles, CA
Previous Ste	PHome	1	Relapse/progression, Disease Progression	Blood	Whole Blood 7.5 mL, Streck DNA tube, Room Temp.	Only option	181 - Amir Goldkorn Lab Los Angeles, CA
T Tevious Ste		1	Relapse/progression, Disease Progression	Blood	Whole Blood 7.5 mL, PAXgene RNA tube, Room Temp.	Only option	181 - Amir Goldkorn Lab Los Angeles, CA
		2	Pre-Randomization	So <u>Tissue from primary site</u>	Blocks FFPE Biopsy	Preferred	201 - SWOG Specimen Repository Columbus, OH
		2	Pre-Randomization	So <u>Tissue from primary site</u>	Unstained Slides Biopsy	Alternate	201 - SWOG Specimen Repository Columbus, OH
		2	Post Radical Prostatectomy	Metastatic tissue from local site	Blocks Prostate Tissue	Preferred	201 - SWOG Specimen Repository Columbus, OH
		2	Post Radical Prostatectomy	Metastatic tissue from local site	Unstained Slides Prostate Tissue	Alternate	201 - SWOG Specimen Repository Columbus, OH
		2	Post Radical Prostatectomy	Metastatic tissue from local site	Blocks Seminal Vesicle Tissue Block	Preferred	201 - SWOG Specimen Repository Columbus, OH
		2	Post Radical Prostatectomy	Metastatic tissue from local site	Unstained Slides Seminal Vesicle Tissue	Alternate	201 - SWOG Specimen Repository Columbus, OH
	ICER IEARCH	2	Post Radical Prostatectomy	Metastatic tissue from local site	Blocks Positive Lymph Node Cores (if nodes dissected)	Preferred	201 - SWOG Specimen Repository Columbus, OH
	WORK	2	Post Radical Prostatectomy	Metastatic tissue from local site	Unstained Slides Positive Lymph Node Cores (if nodes dissected)	Alternate	201 - SWOG Specimen Repository Columbus, OH
		2	Relapse/progression, At Disease Progression	Tissue from primary site	Blocks	Preferred	201 - SWOG Specimen Repository Columbus, OH

Community Oncology Research Program

m of the National Cancer Institute e National Institutes of Health

Specimen Tracking – Log a Specimen

v:	SELECT ONE OR MORE OF THESE <u>REQUIRED</u> FILTERS AND CLICK APPLY TO DISPLAY SPECIMEN LIST	Optional additional filter	
	Lab = 201 - SWOG Biospecimen Bank ✓	Registration Step =	Apply Reset
	Specimen/Material Type = Blood		
	Submission Timepoint = All		

Study Number: S1802

Registration Step	Submission Timepoint	Specimen or Material Type	 This specimen has been logged already This specimen was reported as unsubmittable 	Material Requirements	Lab
1	Baseline, Pre-Registration	😵 <u>Blood</u> Whole Blood	5 mL, Purple Top EDTA Tube, Room Temp.		201 - SWOG Biospecimen Bank Columbus, OH





Specimen Tracking – Shipping

View Packing List

Shipment 351190 successfully recorded on 3/8/2024 5:47:23 PM (Pacific time) by Phyllis Goodman

Shipment 351190 Contents:

Shipment Date: * 3/11/2024

Generate Shipment Label (optional)
Specimen Manager

Patient	Study	Specimen Numbe	r Specimen	Quantity	Tmepoint	Collection Dat	Specimen Label
298270	S2104	<u>2475196</u>	Blood - Whole Blood	1	Other, 6 months after registration	3/8/2024	Label to use: <u>Basic label</u> Patient #: 298270
298270	S2104	<u>2475197</u>	Blood - Buffy coat	2	Other, 6 months after registration	3/8/2024	Patient Initials: <i>M, D D</i> Collection Date: 3/8/2024 Specimen Type: Whole Blood
Ship To: Address		Star Solic Natio 700	- SWOG Biospecimen Ba dard Tissue,Myeloma & Lym onwide Children's Hospit Children's Dr, WA1340 mbus, OH 43205	phoma Div			Label to use: <u>Basic label</u> Patient #: 298270
		ing Number:					Patient Initials: M, D D
		-	-)				Collection Date: 3/8/2024
(e.g. Fed	eral Expi	ress tracking numbe) is Goodman				Collection Date: 3/8/2024 Specimen Type: Buffy coat
(e.g. Fed Name of	eral Expr Shippe	ress tracking number					Collection Date: 3/8/2024 Specimen Type: Buffy coat





·	Study ID: S2104 - 1	Page 1 of 2	Packing Lis	
nmary of Contents		4		
d/Whole Blood/Wren Buffer Red Top Tube Qty: 1 d/Buffy coat/1mL alignots in 2mL cryovials Oty: 2				
EN PACKING THE SHIPMENT, REMEMBER THE FOLLOV	/ING:			
Include a copy of this Packing List (all pages)			4	
Note that the expected shipping temperature for the specim				
Confirm that all specimens listed on the following page(s) a			ist for Shipment 351190 , SWOG Patien	
rmation see ("Label To Use") el templates can be found at <u>SWOG.org >> Clinical Trials >></u>	SWOG Patient ID: 2982		OG Study ID: S2104 - 1	Page 2 of 2
mission Procedures	Specimen: Blood / Whole Bl	ood / Wren Buffer Red T	op Tube	
oment Information	Timepoint: Other, 6 m	nonths after registration		
		10:00:00 AM	Specimen Label	
Shipment Tracking	Quantity: 1 SWOG Specimen #: 2475196			
Number: Comments: (None)			Label to use: <u>Basic label</u>	
Shipped date: 3/11/2024 Shipped By: Phyllis Goodman (pgoodman@fredhu	Specimen: Blood / Buffy coa	at / 1mL aliquots in 2mL	Patient Initials: M, D D	
Wisconsin NCI Community Oncology Re 1000 North Oak Avenue	-	nonths after registration	Collection Date: 3/8/2024	
Marshfield, WI 54449 (206) 667-2768	Date Collected: 3/8/2024 Quantity: 2	10:10:00 AM	Specimen Type: Whole Blog	od
	SWOG Specimen #: 2475197			<u> </u>
SWOG Institution Head Deanna Cole, MPH (<u>cole.deanna@ma</u> CRA: (715) 221-6711				
Sent To: SWOG Biospecimen Bank	Shipment Contact Informati	on	Label to use: <u>Basic label</u>	
Solid Tissue, Myeloma & Lymphoma Div Nationwide Children's Hospital	Shipment Contact Informati		Patient #: 298270	
700 Children's Dr, WA1340 Columbus, OH 43205	Shipped By: Ph	yllis Goodman (<mark>pgoodman@fr</mark>	edhute Patient Initials: M, D D	
(614) 722-2865		sconsin NCI Community Oncolo 00 North Oak Avenue	Collection Date: 3/8/2024	
Note to Recipient: Use this packing list to confirm the con	Ma	rshfield, WI 54449	Specimen Type: Buffy coat	
SWOG Specimen Tracking system at <u>ht</u>	(2)	06) 667-2768	(-
	SWOG Institution Head De	anna Cole, MPH (<mark>cole.deanna</mark> 15) 221-6711	@mars	
	Ска: (/	13) 221-0/11		

Specimen Expectations - Metrics

- Baseline specimens for
 - 1. Eligibility, stratification or future endpoint determination
 - ➔ Initial Forms Set metric
 - 2. Banking or future TM studies
 → Specimen metric

• All other post-baseline specimens → Specimen metric





Specimen Expectations – Current Report

EXPECTATIONS

Filter Criteria						
SWOG Patient ID:	Study:	-	_	SWOG Investigator ID:	Disease Type: - ALL - 🗸	
Registrations after: (mm/dd/yyyy)	Items due*: O Before O After *Within upcoming 90 days only	(m	nm/dd/yyyy)	Expectation Category: Specimen	IPR: - ALL - 🗸	
Institution CTEP ID: -ALL-			L			
		Apply	leset			
					Export Report Da	ata to Excel

2/9/2023 4:53:29 PM

Data Management Institution: Upstate NCORP (UPSTATE) Follow-up Institution: Upstate NCORP (UPSTATE)


SWOG Patient ID	Initials	Study	Institution CTEP ID	Investigator	RegDate	Last Contact Date	Status	Due Date	Expectation	Days Overdue	IPR		
289123	C,JA	S1802-1			01/27/2022	01/27/2022	А	02/11/2022	Blood submission/Pre-Registration, 5 mL purple top EDTA Tube	363	SPEC		
										03/24/2022	Tissue submission/Pre-Treatment Metastatic Tissue	322	SPEC
								03/24/2022	Tissue submission/Pre-Treatment Primary Tissue	322	SPEC		
281933	F, PJ	S1608-1			08/13/2020	01/26/2023	А	02/28/2023	Blood submission/30-month, EDTA tubes				
								02/28/2023	Blood submission/30-month, ctDNA Streck tubes				
283163	N,KD	S1803-2		200000	11/30/2020	01/12/2023	А	12/16/2022	Bone Marrow Aspirate/24-month, aspirate or whole blood for banking	55	SPEC		
								12/16/2022	Bone Marrow Aspirate/24-month, for MRD	55	SPEC		





Specimens that can't be submitted

- If a specimen cannot be submitted
 - "Notify that Specimen Cannot be Submitted" function on Specimen Tracking resolves the expectation



Common reasons:

- Participant unable to come in
- Participant refused
- Staff oversight
- Collection problems





A program of the National Cancer Institute of the National Institutes of Health

Common Specimen Expectation Problems

- 1. I submitted the specimen but it keeps showing up on my Expectation Report, help!
 - a. Check Specimen Manger, to confirm that the correct specimen was chosen when it was logged in.
 - b. If the **wrong Specimen Type** or **Timepoint** was chosen, you need to contact <u>technicalquestion@crab.org</u> to make the correction.
- 2. My patient changed their consent to submitting specimens, why won't the expectation go away?
 - a. Check that the consent was properly updated.
 - b. Changing consent will only stop future expectations from getting posted. If the specimen was expected prior to updating the consent, it will still appear. Use the "Notify that a specimen..." function to resolve.





Common Specimen Expectation Problems: Progression/Relapse Specimens

- 1. I submitted the progression specimen, why is it still showing up on my report?
 - a. This happens if you submit a "progression" specimen prior to completing the form that indicates the patient progressed.
 - b. The form "triggers" the expectation and it should "back-resolve" but if it didn't, contact your data coordinator at the disease-specific email.
- 2. My patient didn't progress/relapse. Why are there progression specimens showing up as due (or overdue).
 - a. Progression/relapse specimens are triggered by a progression being noted in Rave. If the data is changed back to "no progression/relapse", the expectation doesn't resolve; you need to contact your data coordinator at the disease-specific email.





Site Tips 'n Tricks: Kaiser Permanente

New patients

- When new patients are identified for a trial, we review the protocol study calendar and biospecimen table
- Utilize the **Specimen Requirements Summary** to evaluate what specimens will be required and what supplies will be needed.

Existing patients

Monthly

• Centrally, we pull and send **SWOG Expectation** list and the SWOG IPR Report to our SWOG site locations.

Weekly or Bi-Weekly

 Research staff are encouraged to also check these reports often for their site and/or patients.







Processing Biospecimens: Kaiser Permanente

Prior to Visit

- 1. Staff maintain **patient calendars** and trackers which include specimens to be collected and upcoming visits.
- 2. Weekly site meetings used to review upcoming patients, specimens required, and specimen kits/supplies needed.
- Prior to scheduled patient visits Kits are pulled and prepped so it is ready for staff who will be completing the visit.
- Required archival tissue is requested from our pathology departments as early as possible, after consent to have in hand ready to ship when due.

After patient visit

- Collected specimen details including Study, Timepoint, Date and Time, Type of Specimen, Type of tubes/collection and shipping information are all charted in the EMR and filed in the patient research chart.
- 2. Keep and file all specimen tracking sheets, requisitions, orders, copies of shipping waybills, collection details in the patient's chart.
- 3. Utilize a brief tracking list style page in patient research shadow file charts for easy review of what date samples are completed and sent.
- **4. Kit inventory is reviewed** <u>at least monthly</u> and kits ordered and/or prepared well in advance





Processing Biospecimens: U Rochester

Use of Research Specialists

- Ensure necessary kits are onsite when needed and are prepared for patients
- Process and ship according to protocol and IATA requirements; keep the protocol handy while processing to ensure accuracy



- Promote familiarity with disease-specific specimens
- Included in weekly team meetings to prepare for study patients
- Facilitate communication when there are last-minute changes





Site Tips 'n Tricks: U Rochester

Use of a Shared Outlook calendar dedicated to specimen management

- Ensures information is available to all when needed
- Facilitates coverage in the event of an unplanned absence
- Success in labelling credited to:
 - Detailed oriented Research Specialists who are instructed to follow the protocol "to the letter" (or comma in this case)
 - Research Specialists come from the medical center processing lab and are incorporated into the team; they are invested in the research.





Conclusions

- SWOG Specimens are important!
 - Valuable resource for running trials as well as research and future trial implications
 - Most SWOG protocols now include specimen collection
- Resources available to help ORPs
 - swog.org
 - Protocol
 - CRA Workbench
 - Specimen tracking
 - Other SWOG ORPs
- Questions? Reach out to study teams or <a>TechnicalQuestion@crab.org







Oishi Symposium: Improving Specimen Submissions to SWOG Biospecimen Bank Thursday, April 4, 2024


Kae Tegtmeier

Business and Project Development Director

Biopathology Center / SWOG Biospecimen Bank











X

Most Common Submission Errors

- 1. Specimen Labeling
 - Missing required data
 - Data on specimen label discrepant with the Specimen Tracking System Packing List
 - Note: either issue may require a waiver to resolve
- 2. Missing pathology report (required for tissue submissions)
- 3. Quantity received is discrepant with quantity on the Packing List





Specimen Labeling: Biofluids

Includes blood, bone marrow, plasma, serum, urine, stool, etc.

Specimen Container/Type	Required Data	Required on <i>each</i> specimen	Can be on package (e.g., plastic bag) for identical specimens
Collection tubes	 SWOG participant ID Participant initials Collection date Specimen type (blood, bone marrow, stool, etc.) 	 SWOG Participant ID Participant initials Specimen type Laterality (bone marrow) – right (R) or left (L) <i>if more than one</i> 	Collection date
Cryovial	 SWOG participant ID Participant initials Collection date Specimen type (plasma, serum, etc.) 	 SWOG Participant ID Participant initials Specimen type 	Collection Date





Biofluid Labeling Examples





Patient #: (054321 Patient Initials: L, FM Collection Date: 1-1-24 Specimen Type: 1-1-24 XSWOG

Blood tube

- Labeled with SWOG participant ID, initials, collection date, and specimen type
- Label placed horizontally or vertically, not covering manufacturer information and expiration date



Frozen plasma or serum

- Labeled with SWOG participant ID, initials, collection date, and specimen type
- Label wrapped around vial with a flag, or overlapping the label itself on the tube





Specimen Labeling – Tissue

Specimen Container/Type	Required Data	Required on <i>each</i> specimen	Can be on package (e.g., plastic bag) for identical specimens
FFPE Block Cassette	 SWOG Participant ID Participant initials Collection date Surgical Pathology ID (SPID)¹ Block Number¹ 	 SWOG Participant ID Surgical Pathology ID¹ Block number¹ 	 Participant initials Collection date Tissue type (if required) Primary tumor (P) Metastatic tumor (M) Normal tissue (N)
FFPE Tissue Slide	 SWOG Participant ID Participant initials Collection date Surgical Pathology ID (SPID)¹ Block Number¹ 	 SWOG Participant ID Surgical Pathology ID¹ Block Number¹ Tissue thickness (microns, if required) 	 Participant initials Collection date Tissue type (if required) Primary tumor (P) Metastatic tumor (M) Normal tissue (N)

¹From the pathology report corresponding to the tissue removal procedure





Pathology Reports and Tissue Types


- Pathology reports are <u>required</u> for formalin-fixed paraffin-embedded (FFPE) tissues including blocks, slides, and scrolls
 - Label pathology report with the SWOG participant ID (handwritten or typed).
 - Do not redact initials, SPID/Accession #, block #, diagnosis, or collection date.
- Before distribution, a SWOG Bank pathologist confirms <u>concordance with</u> the institutional diagnosis
 - Quality assurance step to confirm if the tissue is acceptable for the planned research
- SWOG Bank definitions of tissue type:
 - **<u>Primary</u>**: the initial source of tumor tissue, including residual tumor from the primary site. Must make biological sense for tumor type (e.g., colon cancer in colon tissue).
 - <u>Metastatic</u>: tumor tissue collected at sites separate from the primary lesion, including local and distant metastatic tumor and residual tumor from the metastatic site (e.g., lung tumor biopsy for prostate cancer)
 - **<u>Normal</u>**: tissue that does not contain tumor, including lymph nodes negative for tumor.






Tissue Labeling Examples





FFPE tissue slides in a slide case

- Slides labeled with SPID, Block #, and SWOG participant ID
- All other labeling requirements on slide case



FFPE tissue block

- Block labeled with SWOG participant ID, SPID, block #
- All labeling requirements on plastic bag.





Labeling Templates

Label	Example Label	Specimen type(s)
Basic labels or MS Word Version for Download	Patient #: Patient Initials (L,FM): Collection Date: Specimen Type:	 Blood/blood products (e.g., plasma, serum, buffy coat) Bone Marrow Aspirate and Bone Marrow Biopsy Urine Stool Other biofluids
Time-based labels or MS Word Version for Download	Patient #: XSWOG Patient Initials (L,FM): Collection Date: Collection Time: Specimen Type:	 Specimens collected for studies where multiple samples are collected during the same day and the lab requires collection time to differentiate them for processing
Tissue Label or MS Word Version for Download	Patient #: XSWOG Patient Initials (L,FM): Collection Date: Surg Path: Block #: Tissue Type:	 FFPE tissue (blocks, slides, scrolls/curls) Frozen tissue
Tissue label (with microns) or MS Word Version for Download	Patient #: XSWOG Patient Initials (L,FM): Collection Date: Surg Path: Microns: Block #: Tissue Type:	FFPE tissue slides or scrolls
Basic with Laterality or MS Word Version for Download	Patient #: XSWOG Patient Initials (L,FM): Collection Date: Specimen Type: Laterality (R or L):	 When the protocol requires indication of laterality, for: Bone Marrow Aspirate Bone marrow Biopsy





Additional Labeling Tips

X

- Label tubes that will be frozen *prior* to freezing
- Printable labels that adhere to frozen surfaces are available at Labtag.com
- Acceptable initials formats:
 - Last, First Middle (L,FM) this is the order on the Packing List
 - First Middle Last (FML)
- Do not cover or remove manufacturer labels (e.g., on collection tubes)
- Do not cover tissue (on FFPE block or slides)
- Use indelible ink for handwritten information (e.g., Moist Mark lab markers, Starstedt permanent marker pens, etc.)







Other Common Specimen Quality Issues

Issue	Prevention	
Specimen that should be frozen arrived thawed or with insufficient dry ice	 Choose an appropriately-sized container – dry ice will sublimate at a rate of 5-10 lbs. every 24 hours. Add dry ice to the bottom ~1/3, add the specimens, and then add dry ice to the top of the container. Include lots of dry ice <i>all year round</i>. 	
Blood / bone marrow is hemolyzed or clotted	 Thoroughly mix the specimen with anticoagulant immediately after collection Do not shake or vortex, but gently invert tube 8 – 10 times after collection. 	
Specimen container is cracked, broken, or leaking	 Always use plastic collection tubes if submitting frozen specimens. Do not overfill cryovials before freezing (~1.5 mL liquid can be frozen in a 2-mL cryovial). Package specimens carefully – if it rattles, don't ship it! Be generous with bubble wrap – it's both a good insulator and specimen protectant. Do not ship cracked, broken, or leaking specimens. 	







Common Specimen Submission Issues

Issue	Prevention
STS Packing List does not match specimens received	 All specimen labeling information (identifiers, collection date, etc.) must correspond with the information entered in the STS. The number of specimens (e.g., number of tubes, vials, glass slides, etc.) received must match the STS packing list. Note: number is the number of specimens, not volume (e.g., one 10-mL tube of blood is 1 specimen, two 5-mL tubes is 2 specimens)
Insufficient Dry Ice	 Include lots of dry ice <i>all year round</i>. Dry ice will sublimate at a rate of 5-10 lbs. every 24 hours
Incorrect specimen type received (e.g., protocol indicates to submit whole blood, and plasma is received)	 Refer to the protocol – use the current version of the protocol If the protocol is unclear – contact the SWOG Bank!





Website Improvements



Transitioned content from webpage to printable PDF pages

Reformatting into charts and bullet points Will continue to add more pictures and diagrams





Specimen Collection and Processing Guidelines for Buffy Coat and Plasma

If protocol-specific collection instructions for peripheral blood and processing instructions for buffy coat and plasma are not provided in the protocol or through a linked resource (usually in Section 15 in SWOG-led protocols), then follow the instructions outlined below.

Plasma is processed from blood collected with anticoagulant (e.g. EDTA, sodium heparin, etc.). Inverting the tube immediately after collection is essential to ensure blood does not clot. Plasma and buffy coat are processed by centrifuging and removing the yellowish-clear layer (plasma) and/or the very thin white or gray-ish layer (buffy coat) – see figure. Note: after processing, plasma looks very similar to serum. If a protocol includes both plasma and serum specimens, it's *imperative* that each tube is labeled with the specimen type (e.g., plasma or serum).

Collecting Peripheral Blood

- Use the protocol-specified Vacutainer tube type.
- If the recommended size of vacutainer tube specified in the clinical trial protocol is not available, then
 other sized tubes may be used to collect the total volume of blood (e.g., if 10 mL of blood is requested,
 then two (2) 5-mL tubes may be used).
- · Pre-label vacutainer tube(s) according to specimen labeling requirements.
- Draw blood from the participant into the vacutainer tube(s). The amount of blood required will vary per protocol; refer to section 15 for the collection volume.
- Immediately after collection, gently invert the tube 5-10 times to thoroughly mix the blood with the anticoagulant and prevent clotting.
- Blood must be processed within 2 hours after venipuncture unless otherwise noted in the protocol. Document
 on the specimen shipping form if the blood was not processed within 2 hours following venipuncture.

Plasma Processing

- Centrifuge the vacutainer tube(s) at 1200 x g for 10 minutes at room temperature.
- 2. Pre-label cryovials according to specimen labeling requirements.
- Using a clean disposable pipette, remove the plasma (yellow-clear liquid above the buffy coat and red blood cell layers). See Figure. No cells or debris should be present in the plasma.
- Dispense 1 mL aliquots of plasma into the pre-labeled 2 mL-capacity cryovials and cap the tubes securely. If the aliquot volume is not specified in the protocol, use as many cryovials as needed to evenly dispense plasma into 1 mL aliquots.
 - 1% BUFFY COAT (white blood cells and platelets)

55% PLASMA-

- The number of vials needed will vary based on the volume of plasma obtained but can be estimated as roughly half of the blood volume collected.
- Immediately freeze plasma vials in an upright position, buried in dry ice or in a -70°C to -80°C freezer until ready to ship.
- If buffy coat is also required, follow instructions below to remove buffy layer. If buffy coat is not requested, then discard remnant cells.

Buffy Coat Processing

- Centrifuge vacutainer tube(s) at 1200 x g for 10 minutes at room temperature. Note: if processing plasma and buffy coat, only one centrifugation is needed.
- 2. Pre-label cryovials according to specimen labeling requirements.
- Using a clean pipette, slowly remove the buffy coat (the thin, cloudy pin or gray-white layer located in between the red blood cells and the plasma; refer to figure below). Avoid aspirating the red blood cells while collecting the buffy coat.
- 4. Split the buffy coat equally into two 2 mL cryovials.
- Immediately freeze vials in an upright position, buried in dry ice or in a -70°C to -80°C freezer until ready to ship. Version Date: 03/27/2024

Specimen Collection and Processing Instructions

Unless otherwise indicated in the protocol, collect and process specimens as outlined in the instructions accessible from the links below.

Important Notes:

- Prior to specimen collection: Verify that the collection tube/container (e.g., for blood, bone marroy etc.) will
 not expire prior to receipt by the SWOG Biospecimen Bank (or protocol-designated laboratory).
- Always refer to the protocol for specimen collection and processing instructions.
 - When the protocol does not provide instructions (or refers to the SWOG website for spectmen instructions), follow the guidelines linked below.
- The pathology report(s) corresponding to the tissue removal surgery must be included with e ch shipment of tissue. Pathology reports must be redacted as indicated here.

Collection and Handling Instructions for FFPE Tissue, Snap-Frozen T ssue and Bone Marrow Biopsy Cores

- Formalin-Fixed Paraffin-Embedded (FFPE) Tissue
- Snap-Frozen Tissue or Bone Marrow Biopsy Cores

Blood Collection and Processing Instructions

- Buffy Coat and Plasma (from Whole Blood)
- Serum from whole block

Bone Marrow Aspirate Collection and Processing Instructions

Bone Marrow Aspirate





of the National Institutes of Health



Your feedback is important!



- Visit the SWOG Biospecimen Bank at Oishi Open Forum
- Email <u>Training@SWOG.org</u>





SWOG Bank Contact Information



Solid Tissue, Myeloma & Lymphoma Division

SWOG Biospecimen Bank #201 614-722-2865 <u>bpcbank@nationwidechildrens.org</u>

SWOG Biospecimen Bank Nationwide Children's Hospital 700 Children's Drive, WA1340 Columbus, Ohio 43205 **Leukemia Division**

SWOG Biospecimen Bank #200 614-722-3270 bpcmglab@nationwidechildrens.org

SWOG Biospecimen Bank Nationwide Children's Hospital 700 Children's Drive, C0825 Columbus, Ohio 43205





Questions on Biospecimens?





Don't forget to visit the Biospecimen Table at Open Forum!







BREAK TIME!

Resuming in 10 minutes





Oishi Symposium Thursday, April 4, 2024

DEI Champions: Lessons Learned & Implications for Future Programming

Speaker

Colmar Figueroa-Moseley, Ph.D., M.P.H. Health Equity & Research Development (HEARD) GI Subcommittee, Co-Chair





Background



- Improving diversity and representativeness in SWOG Cancer Research Network (SWOG) clinical trials is critical for addressing disparities in prevention, detection, treatment, supportive care, and mortality among patients with cancer diagnosis.
- Understanding the needs of underrepresented groups (URGs) and building relationships and trust between these populations and researchers can help overcome barriers to study recruitment.
- SWOG developed a formal organization structure to provide evidence-based guidance for increasing diverse representation in SWOG research.






Structure



DEI at SWOG is integrated in the group mission and values







Structural Focus: DEI Champions

- 2-year funded program by Genentech and The Hope Foundation
- 5 Champions were chosen for the following committees:
 - Breast
 - Genitourinary
 - Gastrointestinal
 - Myeloma
 - Lung





Structural Focus: DEI Champions

- X
- Champions were tasked to work with research committees and study teams to:
 - Identify action plans to increase diversity and equity in research participation
 - Provide tools, evidence, and strategies to reduce disparities and improve study outcomes
 - Implement strategies for research program modifications and policies





Factors That Affected Champion Committee Integration


- Culture
- Structure
- Readiness for Change
- Leadership







Other Champion Program Challenges



Recommendations & Opportunities

- Understand Burden of Disease in Communities of Interests (Veterans, Rural, SOGI, Women, BIPOC)
- Opening studies at sites with high rates of underrepresented groups
- Collaborate with statisticians on the Inclusion and Planned Enrollment section from capsule phase to protocol opening
- Make eligibility criteria less burdensome and inclusive
- Protocols developed with aims for specific populations







Rebranding Champion Program




- DEI Champions program is now known as Champions of Equity & Engagement in Research (ChEER)
- Applications were due in February 2024
- Review and Interviews in April 2024
- ChEER orientation in May 2024
- Selecting 2 Champions in 2024
- Next Cohort--Lead by Champion Alumna Dr. Jessica McDermott, M.D.
- For more information:

https://thehopefoundation.org/swog-cheer-program/





Sometimes A New Perspective Is All We Need.







X

Acknowledgements: Contributing Co-Authors

- Lucy Gansauer, MSN, RN, OCN, CCRP
- Jessica McDermott, MD
- Gayathri Nagaraj, MD
- Manuel Espinoza-Gutarra, MD
- Patricia Robinson, M.D.
- Allison Caban-Holt, Ph.D.
- Rick Bangs, M.B.A.





Acknowledgements





Genentech

A Member of the Roche Group







Contact Information:

Colmar Figueroa-Moseley, Ph.D., M.P.H.

cfigueroamoseley@swog.org













BREAK TIME!

Resuming in 10 minutes





Oishi Symposium: SWOG QA Audits Top Ten Deficiencies Thursday, April 4, 2024

Speaker

Laura Gonzales, BSN, MA, RN, OCN SWOG Quality Assurance Manager





#10 Failure to Return IND within 90 Days of End of Use

•QA recommendations:

- Review Chapter 6 of the ORP Manual "Drug Ordering and Maintenance"
- Review Section in Protocol related to IND accountability
- Develop plan to communicate study closures to pharmacy staff





#9 Failure to Implement Revision/Update with 30 days of notification

•QA recommendations:

Monitor CTSU Bi-Monthly Broadcast







#8 Failure to Notify Patient of New Risks

- QA recommendations:
 - Review revision/update notifications to determine if patient notification is required
 - Document patient notification in research record





#7 Treatment Not per Protocol



- QA recommendations:
 - Refer to Treatment Section in protocol for specific treatment guidelines
 - For treatment questions, refer to Protocol Contacts page or Section 7.0: "For treatment or dose modifications, contact..."





#6 QOLs/PROs Not Administered per Protocol



- QA recommendations:
 - Refer to protocol for QOL/PRO administration timepoints
 - If ePRO, document patient completion in research record
 - If patient not seen in clinic, PROs/QOLs can usually be sent to patient or administered over the phone





#5 Disease Assessments Not Performed per Protocol

- QA recommendations:
 - Refer to Disease Assessment section in protocol for timepoints
 - If disease assessment not performed, document reason in research record





#4 Late Submission of SAEs



- QA recommendations:
 - Refer to AE/SAE Section in protocol for timeline for submitting SAEs
 - If you have any questions about SAE submission, contact SWOG SAE Team at <u>adr@swog.org</u>





#3 Failure to Verify Eligibility Prior to Registration



- QA recommendations:
 - Refer to Eligibility Section of protocol
 - Have a second person to verify patient meets all eligibility requirements
 - Registering/Treating Investigator sign Eligibility Checklist/Affirmation of Eligibility prior to registration





#2 Delinquent Data Submission



- QA recommendations:
 - Refer to Section 14 of protocol for data submission guidelines
 - Refer to SWOG Best Practices document for data submission guidelines not covered in specific protocols
 - If any questions about data submission, contact SDMC listed on Protocol Contacts page of protocol





#1 Specimens Not Submitted per Protocol

- QA recommendations:
 - Refer to Section 15 of the protocol for specific guidelines
 - Confirm patient has consented to specimen submission and that it is reported correctly in OPEN
 - If specimen cannot be submitted, document in the research record and in Specimen Tracking





Questions?

qamail@swog.org





Questions?

qamail@swog.org







BREAK TIME!

Resuming in 10 minutes





ZSWOG CANCER RESEARCH NETWORK

Oishi Symposium: Tour of SWOG Website Thursday, April 4, 2024

Tour Guide Christine Magner, Clinical Research Data Operations Supervisor





I need to reach out to another site. How can I find out who the Lead ORP at a SWOG site is?

- A. Google to the rescue!
- B. Use the SWOG directory
- C. Call the site in question and ask to speak to the Lead ORP at their site.
- D. Anyone remember the yellow pages????





I need to reach out to another site. How can I find out who the Lead ORP at a SWOG site is? 🛛 🛷 🛛



I need to reach out to another site. How can I find out who the Lead ORP at a SWOG site is?

B. Use the SWOG directory

www.SWOG.org

└→ The SWOG Network

└→ Directory

→ Defaulted to individual. If searching for site, click under SEARCH button





My patient is moving. How can I find other sites that have the protocol open?

- A. Google to the rescue again!
- B. Go to nih.gov and poke around
- C. Use SWOG.org
- D. Have the patient research the area for hospitals then cross reference them with the SWOG roster





My patient is moving. How can I find other sites that have the protocol open?



My patient is moving. How can I find other sites that have the protocol open? C. Use SWOG.org

www.SWOG.org

- → Clinical Trials
 - → Clinical Trials Search
 - → Enter Protocol number
 - └→ Click on protocol title
 - → Click Trial Locations button
 - └→ Can enter key words or narrow down by institution type or state
 - → Contact info found by clicking site name





Cool! I found a facility for our patient to get treatment and remain on protocol down in Scottsdale. Now what?

- A. Google to the rescue! Eventually this has got to be the right answer, right?
- B. Consult SWOG Policies and Procedures
- C. Use swog.org
- D. Reach out to site and see if they are accepting new patients





Cool! I found a facility for our patient to get treatment and remain on protocol down in Scottsdale. Now what?

20



Cool! I found a facility for our patient to get treatment and remain on protocol down in Scottsdale. Now what?

B. Consult SWOG Policies and Procedures

CRA Workbench → Resources → SWOG Policies → Policy #30 – Responsibility for Patient Follow-Up





My Lead ORP sends me the expectation report every month. I've submitted the data but how do I know if it came off the expectation report?

- A. Verify the item came off the list the following month when you receive a new report
- B. Call the Data Coordinator
- C. E-mail expectationreportquestion@crab.org
- D. Look up the current report yourself at <u>www.swog.org</u>





My Lead ORP sends me the expectation report every month. I've submitted the data but how do I know if it came off the expectation report?



a National Cancer Institute program

A program of the National Cancer Institute of the National Institutes of Health

≪ C

My Lead ORP sends me the expectation report every month. I've submitted the data but how do I know if it came off the expectation report?

D. Look up the current report yourself at swog.org

<u>CRA Workbench</u> → Patient Reports/Data Quality → Expectations





I recently received the CRA Newsletter. It sure is snazzy. I wish I hadn't waited so long to sign up to receive it. I wonder what I've missed. Do I have access to previous issues? How can my coworkers receive it?

- A. Unfortunately, no, but some info is better than none
- B. Unfortunately, no, but we're working on it
- C. Heck yes, you can sign up to receive it and view archived editions via the CRA Workbench
- D. Heck yes, just send an e-mail to <u>CRANewsletter@crab.org</u>





I recently received the CRA Newsletter. It sure is snazzy. I wish I hadn't waited so long to sign up to receive it. I wonder what I've missed. Do I have access to previous issues? How can my coworkers receive it?



I recently received the CRA Newsletter. It sure is snazzy. I wish I hadn't waited so long to sign up to receive it. I wonder what I've missed. Do I have access to previous issues? How can my coworkers receive it?

C. Heck yes, you can sign up to receive it and view archived editions via the CRA Workbench

<u>CRA Workbench</u> (you can view current one & join the mailing list here)

- └→ Resources
 - → CRA Newsletter Archive





SWOG is coming for an audit. I'm trying not to freak out. What now?

- A. SWOG CRA Workbench has a section for that
- B. Time to pray
- C. All hands on deck! Get all of your data cleaned up on all studies, just to be safe
- D. Vodka never hurt





SWOG is coming for an audit. I'm trying not to freak out. What now?



SWOG is coming for an audit. I'm trying not to freak out. What now?

A. SWOG CRA Workbench has a section for that

CRA Workbench → Popular Resources → SWOG QA / Audits / Monitoring → 6 different categories of help including Site preparation for an Audit






We only registered 2 pts to this study. 1 patient is deceased and the other has completed follow-up. Can we close this study out at our site?

- A. Yes, if no patients are living and/or all queries are closed and expectations resolved
- B. No, all studies must remain open through your IRB for eternity
- C. Maybe. Call your Data Coordinator and see what your options are
- D. Consult CRA Workbench to see if the study requires follow-up





We only registered 2 pts to this study. 1 patient is deceased and the other has completed follow-up. Can we close this study out at our site?



A program of the National Cancer Institute of the National Institutes of Health

Ø 0

We only registered 2 pts to this study. 1 patient is deceased and the other has completed follow-up. Can we close this study out at our site?

D. Consult CRA Workbench to see if the study requires follow-up

CRA Workbench

→ Study Reports

→ Studies with no required follow-up





My coworker attended the CTTC yesterday and got a 'cool' date wheel. How do I get one?

- A. Google to the rescue...maybe this time!
- B. You can order one through swog.org
- C. Sign up to attend next spring's CTTC
- D. You don't want one





My coworker attended the CTTC yesterday and got a 'cool' date wheel. How do I get one?

Ο

0

A. Google to the rescue...maybe this time! B. You can order one through swog.org C. Sign up to attend next spring's CTTC D. You don't want one

Start the presentation to see live content. For screen share software, share the entire screen. Get help at pollev.com/app

I 📎

My coworker attended the CTTC yesterday and got a 'cool' date wheel. How do I get one?

D. You don't want one, seriously!

CRA Workbench └→ Tools └→ Date Counter





How can I make sure that I'm uploading the right document and that it will resolve the expectation?

- K
- A. Be sure to redact all patient identifiers, both in the document and in the title of the document
- B. Do not include any special characters, especially #, to the name of any document
- C. Be certain that the correct Type of Procedure is selected
- D. Ensure that the SWOG Patient number, Pt initials and SWOG Study number is on at least one page
- E. All of the above





How can I make sure that I'm uploading the right document and that it will resolve the expectation?

A. Be sure to redact all patientB. Do not include any specialC. Be certain that theidentifiers, both in the document andcharacters, especially #, to thecorrect Type ofin the title of the documentname of any documentProcedure is selected

D. Ensure that the SWOG Patient number, Pt initials and SWOG Study number is on at least one page

E. All of the above

≪⁄ (

Start the presentation to see live content. For screen share software, share the entire screen. Get help at **pollev.com/app**

a National Cancer Institute program

A program of the National Cancer Institute of the National Institutes of Health How can I make sure that I'm uploading the right document and that it will resolve the expectation?




E. All of the above

Let's review some examples.







PATHOLOGY CONSULT

Interpretation:

Words, words and more words. Row, row, row your boat, gently down the stream. Merrily, merrily, merrily ife is but a dream.

Clinical Information: Brief clinical history: 51yo with a wonderful life and minimal complaints.

Procedure:

Pre-operative diagnosis: single Post-operative diagnosis: married, child, a whole lot more responsibility and a whole lot less privacy, free time and spare money.

Gross Description:

Words, words and more words.

Comment:

Mr. Magnigorium came into clinic to have a lovely chat with our staff. Words, words and more words (Humpty Dumpty)sat on a wall (Humpty Dumpty) had a great fall; All the king's horses and all the king's men, Couldn't put (Humpty) together again.

Impression:

The wheels on the bus go round and round Round and round Round and round The wheels on the bus go round and round All through the town.

The wipers on the bus go swish, swish, swish, swish, swish, swish, swish, swish, swish The wipers on the bus go swish, swish, swish All through the town.

The people on the bus go chat, chat, chat, chat, chat, chat, chat, chat, chat The people on the bus go chat, chat, chat All through the town.

The horn on the bus goes beep, beep, beep, beep, beep, beep, beep, beep, beep, beep All through the town.

1 of 2

Electronically Signed by Dr. FeelGood on this date at this time.

March 11, 2024 11:49 am

Not So Perfect Example

- Protected Health Information (PHI) visible
- Redaction Issues
 - Inappropriate redaction method
 - Incorrect information redacted
- Missing study patient identifiers





a National Cancer Institute program

A program of the National Cancer Institute of the National Institutes of Health



PATHOLOGY CONSULT

Interpretation:

Words, words and more words. Row, row, row your boat, gently down the stream. Merrily, merrily, merrily, merrily life is but a dream.

Clinical Information:

Brief clinical history: 51yo with a wonderful life and minimal complaints

Procedure:

Pre-operative diagnosis: single Post-operative diagnosis: married, child, a whole lot more responsibility and a whole lot less privacy, free time and spare money.

Gross Description:

Words, words and more words.



Impression

The wheels on the bus go round and round Round and round Round and round The wheels on the bus go round and round All through the town.

The wipers on the bus go swish, swish, swish, swish, swish, swish, swish, swish, swish The wipers on the bus go swish, swish, swish, swish All through the town.

The people on the bus go chat, chat,

The horn on the bus goes beep, beep, beep, beep, beep, beep, beep, beep, beep, beep All through the town.

Electronically Signed by Dr. FeelGood on this date at this time.

1 of 2

Perfect Example

- All protected health information (PHI) redacted
- Appropriate redaction method (blackout)
- Study patient identifiers included on at least one page
 - SWOG patient number
 - Patient initials
 - SWOG study number



If a required specimen is not available for submission, you should

- A. Use the "notify that specimen cannot be submitted" link in the Specimen Tracking System
- B. Reach out to the Data Coordinator to ask them to remove the expectation for that specimen
- C. Do nothing. There's no specimen to submit and therefore, nothing to enter
- D. None of these answers are correct





If a required specimen is not available for submission, you should 0 Ω O C. Do nothing. There's no specimen to D. None of these A. Use the "notify that specimen cannot be B. Reach out to the Data Coordinator to ask submitted" link in the Specimen Tracking submit and therefore, nothing to them to remove the expectation for that answers are System specimen enter correct Start the presentation to see live content. For screen share software, share the entire screen. Get help at **pollev.com/app**

a National Cancer Institute program

A program of the National Cancer Institute of the National Institutes of Health

If a required specimen is not available for submission, you should

A. Use the "notify that specimen cannot be submitted" link in the Specimen Tracking System

CRA Workbench

└→ Resources

→ SWOG Frequently Asked Questions (FAQ)
 → Specimen Submission
 → Item #2






The labs for my patient were reported in onehundredth but the SWOG form is only asking for reports in tenth. Is it ok to round?

- A. No, you should report to the hundredth if the field allows, otherwise leave it blank
- B. No, you should enter the value as close as you can and specify the actual value in the Comments section of the form
- C. No, SWOG does not allow rounding. Go back to the Treating Doctor for advice on how to report
- D. None of these answers are correct





The labs for my patient were reported in one-hundredth but the SWOG form is only asking **@ 0** for reports in tenth. Is it ok to round?



of the National Institutes of Health

The labs for my patient were reported in onehundredth but the SWOG form is only asking for reports in tenth. Is it ok to round?

D. None of these answers are correct because SWOG does allow rounding for tumor measurements, dosing, and labs.

CRA Workbench

→ CRA Manual (for Oncology Research Professionals)
 → Chapter 16 General Forms and Guidelines
 → Page 2






My patient missed their appointment today and would like to come back on Monday for treatment. I don't see protocol windows specified in the protocol. Will this be ok?

- A. Yes, just be sure to document the reason for the missed appointment in the Comments Section of the treatment form
- B. No, if the patient missed their appointment, the cycle is considered skipped
- C. Yes, if the delay is no longer than the maximum treatment delay allowed in section 7 of the Protocol
- D. Maybe. Call the Data Coordinator for the study to find out
- E. None of these answers are correct





My patient missed their appointment today and would like to come back on Monday for treatment. I don't see protocol windows specified in the protocol. Will this be ok?



A program of the National Cancer Institute of the National Institutes of Health

≪⁄ (

My patient missed their appointment today and would like to come back on Monday for treatment. I don't see protocol windows specified in the protocol. Will this be ok?

E. None of these answers are correct because when the protocol doesn't specify protocol windows, there is a SWOG Standard available in the SWOG Best Practices Memo

CRA Workbench

- → Resources
 - → Best Practices for SWOG Study
 - → Bottom of Page 1





I'm trying to submit data on Study S1007 and I can't find it in Rave. How am I supposed to get this follow-up form in?

- A. Reach out to CTSU to find out why you aren't seeing the study
- B. Call your Data Coordinator to find out why you aren't seeing the study
- C. This could be a Legacy study and data is not collected in Rave
- D. Ensure that the study is still open and collecting data





I'm trying to submit data on Study S1007 and I can't find it in Rave. How am I supposed to get this follow-up form in?

0

A. Reach out to CTSU to find out whyB. Call your Data Coordinator to find out
why you aren't seeing the studyC. This could be a Legacy study and
data is not collected in RaveD. Ensure that the study is stillyou aren't seeing the studywhy you aren't seeing the studydata is not collected in Raveopen and collecting data

Start the presentation to see live content. For screen share software, share the entire screen. Get help at pollev.com/app

a National Cancer Institute program

O

A program of the National Cancer Institute of the National Institutes of Health

c 🖉

I'm trying to submit data on Study S1007 and I can't find it in Rave. How am I supposed to get this follow-up form in?

C. This could be a Legacy study and data is not collected in Rave

CRA Workbench

→ Patient Management (Non-Rave Studies)

- → Data submission for Non-Rave Studies






With OPEN, RAVE, and all the tools in CTSU, why is the CRA Workbench still relevant?

- A. It's the only data entry mechanism for pre-RAVE studies
- B. Reports include patients on both RAVE and pre-RAVE studies
- C. Includes critical SWOG-specific information such as CRA Manual, Best Practices, and Policies
- D. It's maintained by SWOG SCMC staff so tools and resources based largely on CRA feedback and requests
- E. All answers are correct





With OPEN, RAVE, and all the tools in CTSU, why is the CRA Workbench still relevant?



a National Cancer Institute program

A program of the National Cancer Institute of the National Institutes of Health

With OPEN, RAVE, and all the tools in CTSU, why is the CRA Workbench still relevant?

E. All answers are correct!

If you need more proof, we encourage you to check it out for yourself!





Bonus Question: Which statements are true about CLASS?

- A. CLASS is a learning management system supported by CTSU
- B. CLASS stands for Compliance, Learning and SOP Solutions
- C. Everybody with an active CTEP-IAM account can access CLASS
- D. SWOG study-specific training can be found in CLASS
- E. All statements are true





Bonus Question: Which statements are true about CLASS?



Bonus Question: Which statements are true about CLASS?

E. All answers are correct!

CTSU.org

└→ CLASS on Dashboard



